Table 1.
Clinicopathological features of the hepatocellular carcinoma patients and relationship with NEAT1 expressions
| Total patients number (n=79) | Patients with NEAT1 expressions |
||||
|---|---|---|---|---|---|
| Low group (n=39) | High group (n=40) | P | OR (95% CI) | ||
| Age | |||||
| ≤55 | 45 | 24 | 21 | 0.417 | 1.448 (0.591-3.543) |
| >55 | 34 | 15 | 19 | ||
| Gender | |||||
| Female | 32 | 17 | 15 | 0.581 | 1.288 (0.542-3.168) |
| Male | 47 | 22 | 25 | ||
| Stage | |||||
| I or II | 51 | 30 | 21 | 0.023 | 3.016 (1.144-7.952) |
| III or IV | 28 | 9 | 19 | ||
| Lymphatic metastasis | |||||
| No | 46 | 31 | 15 | 0.001 | 6.458 (2.360-17.677) |
| Yes | 33 | 8 | 25 | ||
| Distant metastasis | |||||
| No | 49 | 27 | 22 | 0.193 | 1.841 (0.732-4.629) |
| Yes | 30 | 12 | 18 | ||
| Tumor size | |||||
| ≤5 | 31 | 19 | 12 | 0.088 | 2.217 (0.881-5.578) |
| >5 | 48 | 20 | 28 | ||
| Cirrhosis | |||||
| No | 32 | 13 | 19 | 0.200 | 0.553 (0.222-1.373) |
| Yes | 47 | 26 | 21 | ||
| Sorafenib resistance | |||||
| No | 54 | 32 | 22 | 0.010 | 3.740 (1.338-10.456) |
| Yes | 25 | 7 | 18 | ||